(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.49%) $79.65
(0.48%) $2.31
(0.59%) $2 354.10
(0.90%) $28.62
(0.24%) $993.20
(0.01%) $0.927
(-0.15%) $10.85
(-0.02%) $0.798
(0.02%) $92.56
Quarter results tomorrow
(bmo 2024-05-10)
Expected move: +/- 10.23%
@ $5.43
発行日: 10 2月 2024 @ 05:55
リターン: -48.07%
前回のシグナル: 2月 8 - 04:00
前回のシグナル:
リターン: 5.44 %
Live Chart Being Loaded With Signals
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases...
Stats | |
---|---|
本日の出来高 | 4 800.00 |
平均出来高 | 88 629.00 |
時価総額 | 5.71M |
EPS | $0 ( 2024-04-01 ) |
次の収益日 | ( $-2.18 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0600 |
ATR14 | $0.0310 (1.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Sapirstein James | Sell | 174 | Common Stock |
2024-04-01 | Romano Sarah | Sell | 75 | Common Stock |
2024-03-15 | Sapirstein James | Sell | 1 887 | Common Stock |
2024-03-15 | Romano Sarah | Sell | 1 120 | Common Stock |
2024-03-13 | Syage Jack | Buy | 15 400 | Common Stock, par value $0.0001 per share |
INSIDER POWER |
---|
93.56 |
Last 95 transactions |
Buy: 5 900 618 | Sell: 1 318 677 |
ボリューム 相関
First Wave BioPharma, 相関
10 最も負の相関 | |
---|---|
BBIO | -0.836 |
NVDA | -0.834 |
LSCC | -0.834 |
ACVA | -0.828 |
PDFS | -0.827 |
BRKS | -0.823 |
OSW | -0.822 |
FTNT | -0.821 |
ADI | -0.821 |
RRGB | -0.82 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
First Wave BioPharma, 相関 - 通貨/商品
First Wave BioPharma, 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2023 |
収益: | $0 |
総利益: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2022 |
収益: | $0 |
総利益: | $-106 207 (0.00 %) |
EPS: | $-461.72 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1 377.25 |
Financial Reports:
No articles found.
First Wave BioPharma,
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。